Home / Tirzepatide / Side effects
Tirzepatide side effects
FDA-approved Zepbound US label (revised 8/2026), pooled weight-loss trials in adults.
Short answer: Stomach and gut effects are the most common: nausea in about 1 in 4 people (25-29% vs 8% on placebo), plus diarrhea, constipation and vomiting. They mostly happen while the dose is being raised and fade over time. About 5-7% stopped because of side effects, vs 3.4% on placebo.
How common each side effect is
| Side effect | Placebo | 5 mg | 10 mg | 15 mg |
|---|---|---|---|---|
| Nausea | 8% | 25% | 29% | 28% |
| Diarrhea | 8% | 19% | 21% | 23% |
| Vomiting | 2% | 8% | 11% | 13% |
| Constipation | 5% | 17% | 14% | 11% |
| Abdominal pain | 5% | 9% | 9% | 10% |
| Indigestion (dyspepsia) | 4% | 9% | 9% | 10% |
| Injection site reactions | 2% | 6% | 8% | 8% |
| Fatigue | 3% | 5% | 6% | 7% |
| Allergic (hypersensitivity) reactions | 3% | 5% | 5% | 5% |
| Burping | 1% | 4% | 5% | 5% |
| Hair loss | 1% | 5% | 4% | 5% |
| Acid reflux (GERD) | 2% | 4% | 4% | 5% |
| Dizziness | 2% | 4% | 5% | 4% |
Percent of people reporting each effect. Zepbound label, section 6.1.
Other numbers worth knowing
| Any stomach or gut side effect | 56% at every dose vs 30% on placebo |
| Stopped because of side effects | 4.8% / 6.3% / 6.7% (5 / 10 / 15 mg) vs 3.4% on placebo |
| Hair loss | 7.1% of women vs 0.5% of men; the label links it to weight loss |
| Heart rate | Average increase of 1-3 beats per minute |
| Gallbladder | Gallbladder inflammation 0.7% vs 0.2% on placebo |
| Pancreatitis | 0.2%, the same as placebo, in the weight-loss trials |
| Low blood sugar | 4.2% vs 1.3% in people with type 2 diabetes; 0.3% in people without |
When side effects happen
The label says most nausea, vomiting and diarrhea "occurred during dose escalation and decreased over time."
Boxed warning
Risk of thyroid C-cell tumors. Tirzepatide caused these tumors in rats; it is not known whether it does in humans. Do not use with a personal or family history of medullary thyroid cancer or MEN 2.
Serious risks on the label
- Severe stomach and gut reactions
- Kidney injury from dehydration (vomiting, diarrhea)
- Gallbladder disease
- Pancreatitis
- Serious allergic reactions
- Low blood sugar with insulin or sulfonylureas
- Diabetic eye disease getting worse (type 2 diabetes)
- Breathing in stomach contents during anesthesia or deep sedation
Not medical advice. Contact your prescriber about side effects that are severe or do not go away, and get urgent care for severe stomach pain, signs of an allergic reaction or trouble breathing.
More on Tirzepatide: dosage and status ·units calculator
Side effects of: Semaglutide · Retatrutide · BPC-157
Questions
- How long do tirzepatide side effects last?
- The label says stomach and gut effects mostly happen while the dose is being increased and decrease over time. Each dose step lasts at least 4 weeks, so effects often flare after a step up and settle before the next.
- Does a higher tirzepatide dose mean more side effects?
- Somewhat. Vomiting went from 8% at 5 mg to 13% at 15 mg, and stopping because of side effects from 4.8% to 6.7%. Nausea was similar across doses (25-29%).
- Does tirzepatide cause hair loss?
- Hair loss was reported by about 5% of people on tirzepatide vs 1% on placebo, mostly women (7.1%). The label ties it to weight loss; no one in the trials stopped the drug because of it.
- Is suicidal thinking a tirzepatide warning?
- Not anymore. The Zepbound label removed the suicidal behavior and ideation warning in February 2026.
Sources
- Zepbound (tirzepatide) US prescribing information, Eli Lilly
- Mounjaro (tirzepatide) US prescribing information, Eli Lilly
- Jastreboff et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). NEJM 2022
Last checked 2026-11-16. How we pick and check sources: methodology.